Carbidopa

Primary Uses

Carbidopa is used to treat the symptoms of Parkinson's disease and other conditions that cause similar movement issues. These symptoms often include tremors (shaking), muscle stiffness, and slow or difficult movement.

It is also used to treat parkinsonism caused by:

• Brain infections (post-encephalitic parkinsonism).
• Carbon monoxide poisoning.
• Manganese poisoning.

Combination Therapy

Carbidopa is never used alone to treat these conditions; it must be taken with levodopa. When taken together, carbidopa helps levodopa work more effectively and can help reduce certain side effects, such as nausea and vomiting, that often occur when levodopa is taken by itself.

In some cases, carbidopa is prescribed as an individual tablet for patients who are already taking a combination carbidopa/levodopa product but need additional carbidopa to better manage their symptoms or side effects.

Mechanism of Action

Carbidopa belongs to a class of medications called decarboxylase inhibitors. It is used in combination with levodopa to improve its effectiveness. While levodopa is the primary treatment for Parkinson's symptoms, it is often broken down by enzymes in the body before it can reach the brain.

Carbidopa works by blocking these enzymes in the bloodstream. This process has two main benefits:

• Increased Effectiveness: By preventing the early breakdown of levodopa, carbidopa ensures that a higher concentration of the medication enters the brain, where it is converted into dopamine to help control movement.
• Reduced Side Effects: When levodopa is converted into dopamine in the bloodstream rather than the brain, it can cause significant nausea and vomiting. Carbidopa reduces these side effects by preventing that conversion from happening outside the central nervous system.

Carbidopa does not cross the blood-brain barrier and does not treat the symptoms of Parkinson's disease if taken alone. It only functions to support the action of levodopa.

Common Side Effects

Carbidopa is most often taken in combination with levodopa. Common side effects associated with these medications include:

• Nausea and vomiting
• Dizziness or drowsiness
• Headache
• Dry mouth
• Constipation
• Loss of appetite
• Trouble sleeping or unusual dreams
• Changes in the sense of taste

Some patients may notice that their saliva, urine, or sweat turns a dark color, such as red, brown, or black. This effect is generally considered harmless.

Serious Side Effects

Seek medical attention immediately if you experience any of the following serious symptoms:

• New or worsening involuntary muscle movements, such as twitching or spasms
• Severe or persistent nausea and vomiting
• Fast, pounding, or irregular heartbeat
• Chest pain
• Fainting
• Mental or mood changes, including confusion, hallucinations, depression, or thoughts of suicide
• Intense or uncontrollable urges, such as compulsive gambling, increased sexual urges, or binge eating
• Extreme drowsiness or falling asleep suddenly during daily activities

Contraindications and Interactions

Carbidopa should not be used by individuals who have taken a non-selective monoamine oxidase (MAO) inhibitor within the last 14 days. It is also generally avoided in people with narrow-angle glaucoma.

Movement and Mental Health

Because carbidopa increases the amount of levodopa that reaches the brain, it may worsen involuntary movements known as dyskinesia. Some people may also experience significant mental health changes, including:

• Hallucinations or seeing things that are not there.
• Psychotic behavior or confusion.
• Intense urges that are difficult to control, such as gambling, increased sexual urges, or binge eating.

Sudden Sleepiness

There are reports of individuals falling asleep without warning during daily activities, including while driving. This can occur even if the person does not feel drowsy beforehand.

Abrupt Discontinuation

Stopping carbidopa and levodopa suddenly or rapidly reducing the dose can lead to a serious condition similar to neuroleptic malignant syndrome. Symptoms may include high fever, muscle stiffness, and changes in mental status.

Medical Precautions

Healthcare providers typically monitor patients with the following conditions more closely:

• Severe cardiovascular or pulmonary disease.
• Bronchial asthma.
• Kidney, liver, or endocrine disorders.
• History of peptic ulcers, as the risk of upper gastrointestinal bleeding may increase.
• History of melanoma or undiagnosed skin lesions, as levodopa has been associated with the potential activation of malignant melanoma.

Pregnancy

There is limited information regarding the safety of carbidopa use during pregnancy in humans. Research in animals using carbidopa in combination with levodopa has shown evidence of skeletal and internal organ malformations. Due to the lack of human data, carbidopa is generally only prescribed during pregnancy if a healthcare provider determines that the potential benefits outweigh the potential risks to the developing fetus.

Breastfeeding

It is currently unknown if carbidopa passes into breast milk. Because many drugs can be excreted in human milk, caution is advised for those who are breastfeeding. It is also important to note that carbidopa is typically taken with levodopa, which may suppress the production of breast milk. Patients should consult with their healthcare provider to weigh the risks and benefits of using this medication while nursing.

Available Forms

Carbidopa is available as a single-ingredient medication in an oral tablet form. It is more commonly found in combination with levodopa or in a triple-combination with levodopa and entacapone.

Oral Formulations

• Tablets: Available as standard immediate-release tablets and orally disintegrating tablets that dissolve on the tongue.
• Extended-release: Available as both tablets and capsules designed to release the medication slowly over a longer period.

Other Formulations

• Enteral suspension: A liquid formulation of carbidopa and levodopa that is administered continuously into the small intestine through a surgically placed tube.

FDA Approval and Indications

Carbidopa is approved by the U.S. Food and Drug Administration (FDA) for use as an adjunct to levodopa. It is indicated for the treatment of symptoms associated with idiopathic Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism resulting from carbon monoxide or manganese intoxication.

The primary regulatory purpose of carbidopa is to inhibit the peripheral metabolism of levodopa. This allows more levodopa to reach the brain and reduces the side effects, such as nausea and vomiting, that occur when levodopa is converted to dopamine outside the central nervous system. Carbidopa has no therapeutic effect when administered alone and must be used with levodopa.

Regulatory Safety and Monitoring

Carbidopa is not a controlled substance and does not currently have any boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) requirements. It is available by prescription only. While it is most commonly dispensed in fixed-dose combination products, it is also available as a single-ingredient tablet for patients who require individualized titration of the carbidopa-to-levodopa ratio.

Approved Formulations

The FDA has approved carbidopa in several formats, including:

• Single-ingredient oral tablets.
• Fixed-dose combination oral tablets (immediate and extended-release).
• Fixed-dose combination enteral suspensions for continuous infusion.
• Fixed-dose combination orally disintegrating tablets.

Risks of Abrupt Discontinuation

It is important not to stop taking carbidopa or change your dosage without consulting a healthcare professional. Suddenly stopping or rapidly reducing the dose of medications used for Parkinson's disease can lead to a serious condition known as neuroleptic malignant syndrome (NMS).

Neuroleptic Malignant Syndrome (NMS)

NMS is a rare but severe reaction that can occur when carbidopa and levodopa are discontinued abruptly. This condition requires immediate medical intervention. Symptoms may include:

• High fever
• Severe muscle stiffness or rigidity
• Confusion or changes in mental status
• Fast or irregular heartbeat
• Changes in blood pressure
• Unusual body movements

If you experience these symptoms after a dose change or after stopping the medication, seek emergency medical care immediately.

Safe Tapering

To avoid withdrawal-like complications and the sudden return of Parkinson's symptoms, doctors typically recommend gradually reducing the dose over a period of time. This tapering process allows the body to adjust safely to the change in medication levels.